Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06043102 · ClinicalTrials.gov registry record · NA
Study Evaluating the Efficacy and Safety of TheraClearX on Mitigating Mild to Moderate Acne
A NA study of Acne, sponsored by Ablon Skin Institute Research Center.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06043102: Completed NA study of Acne, sponsored by Ablon Skin Institute Research Center.
NCT06043102 is a NA study of Acne that has completed, run by Ablon Skin Institute Research Center. The registered enrollment target is 30 participants, below the 141-participant average among 26 other Acne trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06043102, a NA study of Acne, has completed, sponsored by Ablon Skin Institute Research Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to further substantiate the effectiveness and safety of TheraClearX as a stand-alone treatment of mild to moderate acne in healthy teenagers and adults ages 12-40 over the course of 7 weeks. Participants will be asked to have TheraClearX treatments weekly for 6 sessions, attend a follow up appointment 2 weeks after the 6th session, have photos taken of their face and answer questionnaires related to their acne.
Primary Outcome
Papule - A small, solid elevation less than 5 mm in diameter. Most of the lesion is above the surface of the skin. Pustule - A small circumscribed elevation less than 5 mm in diameter that contains yellow-white exudate. Nodule - An inflammatory lesion greater than or equal to 5 mm in diameter. Cyst - An inflammatory lesion that contains yellow-white exudate that is greater than or equal to 5mm in diameter.
Conditions Studied
Interventions
- DEVICE TheraClearX
Study Locations (1)
California
- Ablon Skin Institute & Research Center - Manhattan Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-05-16 |
| Est. Completion | 2023-09-18 |
| Phase | NA |
What the finished NCT06043102 record still lists
NCT06043102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 141-participant average among 26 other Acne trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 1 intervention - of which TheraClearX is the first listed.
NCT06043102 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06043102 about?
NCT06043102 is a clinical study titled "Study Evaluating the Efficacy and Safety of TheraClearX on Mitigating Mild to Moderate Acne". The goal of this clinical trial is to further substantiate the effectiveness and safety of TheraClearX as a stand-alone treatment of mild to moderate acne in healthy teenagers and adults ages 12-40 over the course of 7 weeks. Participants will be asked to have TheraClearX treatments weekly for 6 ses...
What is the current status of trial NCT06043102?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2023-05-16. Estimated completion is 2023-09-18.
What conditions does trial NCT06043102 study?
This clinical trial studies the following conditions: Acne.
What interventions are being tested in trial NCT06043102?
The interventions under investigation include: TheraClearX (DEVICE).
Who is sponsoring clinical trial NCT06043102?
This trial is sponsored by Ablon Skin Institute Research Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06043102 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06043102's enrollment target sits among peer trials
30 20th of 26 higher than 7 of 26 other Acne trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
ACTIVE NOT RECRUITING · NA
-
The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation
COMPLETED · NA
-
An Exploratory Investigation of a Male Focused Skincare Supplement
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI